Detalhe da pesquisa
1.
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
J Transl Med;
22(1): 326, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38566102
2.
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
BMC Med;
20(1): 197, 2022 05 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35644609
3.
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
World J Surg Oncol;
15(1): 12, 2017 Jan 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28069039
4.
Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.
Support Care Cancer;
23(3): 635-41, 2015 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25155313
5.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Lancet Oncol;
15(2): 213-22, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24439929
6.
Lung cancer treatment disparities in China: a question in need of an answer.
Oncologist;
19(10): 1084-90, 2014 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25223463
7.
Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Thorac Cancer;
15(14): 1119-1131, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38558529
8.
Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions.
Cancers (Basel);
16(2)2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38254793
9.
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study.
Ther Adv Med Oncol;
16: 17588359241229435, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38333112
10.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Sci Bull (Beijing);
69(4): 535-543, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38185589
11.
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.
Oncoimmunology;
13(1): 2340154, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38601319
12.
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
J Thorac Oncol;
19(4): 601-612, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981218
13.
Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
J Cancer Res Clin Oncol;
149(7): 2987-2995, 2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35838839
14.
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Lung Cancer;
175: 68-78, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36473332
15.
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.
J Immunother Cancer;
11(7)2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37463790
16.
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study.
Cell Rep Med;
4(2): 100911, 2023 02 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36657446
17.
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
Transl Lung Cancer Res;
12(1): 127-140, 2023 Jan 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36762057
18.
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Mol Oncol;
17(8): 1581-1594, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37078460
19.
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Cancer Cell;
41(10): 1763-1773.e4, 2023 10 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37816331
20.
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Nat Med;
29(8): 2079-2086, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37488286